Edition:
United States

Obseva SA (OBSV.OQ)

OBSV.OQ on NASDAQ Stock Exchange Global Select Market

15.72USD
3:59pm EST
Change (% chg)

$0.34 (+2.21%)
Prev Close
$15.38
Open
$15.41
Day's High
$15.74
Day's Low
$14.89
Volume
14,085
Avg. Vol
19,550
52-wk High
$20.31
52-wk Low
$9.05

Latest Key Developments (Source: Significant Developments)

ObsEva Reports Q4 Loss Per Share $0.48
Friday, 9 Mar 2018 08:47am EST 

March 9 (Reuters) - Obseva Sa ::OBSEVA REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q4 LOSS PER SHARE $0.48.Q4 EARNINGS PER SHARE VIEW $-0.56 -- THOMSON REUTERS I/B/E/S.EXPECTS 12 WEEK RESULTS FROM PHASE 2B EDELWEISS CLINICAL TRIAL OF OBE2109 FOR TREATMENT OF ENDOMETRIOSIS, IN MID-2018.EXPECTS INITIAL EFFICACY RESULTS FROM PHASE 2A PROLONG CLINICAL TRIAL OF OBE022 IN PRE-TERM LABOR IN LATE 2018.  Full Article

Obseva Reports Positive Topline Results From Implant2 Phase 3 Clinical Trial Of Nolasiban In IVF
Monday, 26 Feb 2018 07:01am EST 

Feb 26 (Reuters) - Obseva Sa ::OBSEVA SA REPORTS POSITIVE TOPLINE RESULTS FROM IMPLANT2 PHASE 3 CLINICAL TRIAL OF NOLASIBAN IN IVF.OBSEVA SA - ‍NOLASIBAN WAS WELL TOLERATED​.OBSEVA SA - FOLLOW-UP DATA FROM IMPLANT2 STUDY WILL INCLUDE LIVE BIRTH RATE, AND 28-DAY NEONATAL SAFETY, EXPECTED TO BE REPORTED IN Q4 OF 2018.OBSEVA SA - ‍IN ET D3 SUBGROUP, THERE WAS A STATISTICALLY NON-SIGNIFICANT 3.1% ABSOLUTE INCREASE IN FAVOR OF NOLASIBAN​.OBSEVA SA - SIX-MONTH INFANT FOLLOW-UP FROM IMPLANT2 STUDY IS EXPECTED TO BE AVAILABLE IN 2019.OBSEVA SA - ‍SAFETY PROFILE OF NOLASIBAN WAS ALSO SIMILAR TO PLACEBO​.OBSEVA SA - ‍NONE OF SERIOUS ADVERSE EVENTS WERE REPORTED TO BE RELATED TO TREATMENT​.OBSEVA SA - ‍IN ET D3 SUBGROUP, THERE WAS 14.0% RELATIVE INCREASE IN ONGOING PREGNANCY RATE AFTER ADMINISTRATION OF NOLASIBAN VERSUS PLACEBO​.OBSEVA SA - ‍IN ET D5 SUBGROUP, THERE WAS RELATIVE INCREASE IN ONGOING PREGNANCY RATE OF 32% AFTER ADMINISTRATION OF NOLASIBAN VERSUS PLACEBO​.OBSEVA SA - ‍IN ET D5 SUBGROUP, ABSOLUTE INCREASE WAS 11.2% IN FAVOR OF NOLASIBAN​.  Full Article

Obseva SA Files For Mixed Shelf Of Upto $200 Mln
Thursday, 1 Feb 2018 05:08pm EST 

Feb 1 (Reuters) - Obseva Sa ::OBSEVA SA FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING.  Full Article

Obseva Initiates Phase 2A Clinical Trial Of Obe022 In Preterm Labor
Tuesday, 5 Dec 2017 07:00am EST 

Dec 5 (Reuters) - Obseva Sa ::OBSEVA INITIATES PROLONG, THE PHASE 2A CLINICAL TRIAL OF OBE022 IN PRETERM LABOR.OBSEVA SA - ‍OBSEVA EXPECTS TO ANNOUNCE PRELIMINARY RESULTS FROM 60 PATIENTS IN PART B OF PROLONG TRIAL IN LATE 2018​.  Full Article

ObsEva SA files for resale of up to 7.5 million common shares‍​
Thursday, 9 Nov 2017 06:27pm EST 

Nov 9 (Reuters) - Obseva Sa :ObsEva SA - files for resale of up to 7.5 million common shares‍​ of co by the selling shareholders - SEC filing.  Full Article

ObsEva SA announces $60 mln private placement with existing and new investors
Tuesday, 10 Oct 2017 08:01am EDT 

Oct 10 (Reuters) - ObsEva SA : :ObsEva SA announces $60.0 million private placement with existing and new investors.ObsEva SA - ‍common shares in offering are priced at $8.00 per share.ObsEva SA - ‍net proceeds from offering are expected to be used to fund research,development of lead compound OBE2109, among others​.  Full Article

Obseva announces completion of patient recruitment
Wednesday, 6 Sep 2017 07:01am EDT 

Sept 6 (Reuters) - Obseva SA ::Obseva SA announces the completion of patient recruitment in the implant2 phase 3 clinical trial in assisted reproductive technology ahead of schedule.Obseva SA - ‍initial results are now expected in Q1 of 2018 from study​.  Full Article

Medicxi Growth I GP limited reports a 5.30 percent passive stake in ‍obseva Sa as of August 22 2017 - SEC filing​
Thursday, 31 Aug 2017 10:25am EDT 

Aug 31 (Reuters) - :Medicxi Growth I GP limited reports a 5.30 percent passive stake in ‍obseva SA as of August 22 2017 - SEC filing​.  Full Article

Obseva SA announces completion of early stage trial evaluating endometriosis drug
Wednesday, 7 Jun 2017 07:01am EDT 

June 7 (Reuters) - Obseva sa -:Obseva SA announces the completion of a phase 1 pk/pd clinical trial evaluating different doses of obe2109 and add-back therapy.Obseva SA - all regimens in phase 1 pk/pd clinical trial were well-tolerated and no safety signal emerged.  Full Article

Obseva reports Q1 loss per share $0.58
Thursday, 18 May 2017 07:01am EDT 

May 18 (Reuters) - Obseva SA :Obseva reports first quarter 2017 financial results and business update.Q1 loss per share $0.58.Obseva SA - as of March 31, 2017, Obseva had cash and cash equivalents of $104.2 million.Obseva SA - research and development expenses were $13.1 million and general and administrative expenses were $2.7 million for quarter ended March 31, 2017.  Full Article

BRIEF-Obseva SA Presents Clinical Data From Phase III Implant 2 Trial Of Nolasiban In IVF At ASRM

* PRESENTS CLINICAL DATA FROM PHASE III IMPLANT 2 TRIAL OF NOLASIBAN IN IVF AT AMERICAN SOCIETY OF REPRODUCTIVE MEDICINE (ASRM) ANNUAL MEETING